Exec. Vice Chairman/CEO/Pres. of Hemispherx Biopharma Inc (HEB, Financial) Thomas K. Equels bought 29,404 shares of HEB on 06/21/2019 at an average price of $4.03 a share. The total cost of this purchase was $118,498.
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is primarily engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. Hemispherx Biopharma Inc has a market cap of $8.580 million; its shares were traded at around $3.90 with and P/S ratio of 13.64. Hemispherx Biopharma Inc had annual average EBITDA growth of 18.80% over the past ten years.
CEO Recent Trades:
- Exec. Vice Chairman/CEO/Pres. Thomas K. Equels bought 29,404 shares of HEB stock on 06/21/2019 at the average price of $4.03. The price of the stock has decreased by 3.23% since.
For the complete insider trading history of HEB, click here
.